
DIFFICULTIES IN DIAGNOSING FABRY DISEASE IN PATIENTS WITH UNEXPLAINED LEFT VENTRICULAR HYPERTROPHY (LVH): IS THE NOVEL GLA GENE MUTATION A PATHOGENIC MUTATION OR POLYMORPHISM? Aladağ N, Ali Barman H, Şipal A, Akbulut T, Özdemir M, Ceylaner S *Corresponding Author: Nesim Aladağ, MD, nesimaladag@hotmail.com, Van Yüzüncü yıl University, Faculty of Medicine, Department of Cardiology, Van, Turkey. Phone: +90 544 961 31 69 / Fax: +90 432 486 54 07 page: 43 download article in pdf format
|
Abstract
Fabry disease (FD) is an X-linked, lysosomal glycosphingolipid
storage disorder that occurs very rarely.
Cardiac involvement may comprise of left ventricular
hypertrophy (LVH), arrhythmias, conduction abnormalities,
heart failure and valvular abnormalities. The goal of
this study was to conduct gene analysis for FD in patients
suffering from unexplained LVH. 120 patients over the
age of 30 who were diagnosed by echocardiography with
idiopathic LVH were included in the study. Patients with
severe hypertension, intermediate valve disease such as
moderate aortic stenosis, known FD, and a family history
of autosomal dominant hypertrophic cardiomyopathy were
excluded from the study. GLA gene mutations were studied
by Sanger sequence analysis in all patients. Of the 120 total
patients included in this study, 69 were female (58%) and
51 were male (42%). The mean age was 60.3 ± 15.7. GLA
gene mutations were detected in three male patients. The
detected mutations are as follows: NM_000169.2:IVS6-
10G>A (c.1000–10G>A), NM_000169.2:c.937G>T
(p.D313Y) (p.Asp313Tyr) and NM_000169.2:c.941A>T
(p.K314M) (p.Lys314Met). Early diagnosis is of vital
importance in FD, which can be treated with enzyme replacement.
Genetic screening in patients diagnosed with
idiopathic LVH by echocardiography is important in the
early diagnosis and treatment of FD. Patients over 30 years
of age with idiopathic LVH should be screened for FD.
Various new polymorphisms can be detected in genetic
screening. Identifying new polymorphisms is important
for knowing the true mutations in FD.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|